Axsome Therapeutics Stock In The News
| AXSM Stock | USD 121.91 0.26 0.21% |
Our overall analysis of Axsome Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Axsome Therapeutics. The specific impact of Axsome Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Axsome Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Axsome Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Axsome Therapeutics Backtesting and Axsome Therapeutics Hype Analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
Axsome |
Axsome Therapeutics Today Top News and Investor Outlook
Axsome Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Axsome and other traded companies coverage with news coverage. We help investors stay connected with Axsome headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Axsome Stock performance. Please note that trading solely based on the Axsome Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Axsome Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Axsome earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Axsome Therapeutics that are available to investors today. That information is available publicly through Axsome media outlets and privately through word of mouth or via Axsome internal channels. However, regardless of the origin, that massive amount of Axsome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Axsome Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Axsome Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Axsome Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Axsome Therapeutics alpha.
Axsome Largest EPS Surprises
Earnings surprises can significantly impact Axsome Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-08-08 | 2018-06-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2016-05-11 | 2016-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2017-08-09 | 2017-06-30 | -0.34 | -0.3 | 0.04 | 11 | ||
2017-11-08 | 2017-09-30 | -0.34 | -0.27 | 0.07 | 20 | ||
2019-08-08 | 2019-06-30 | -0.33 | -0.41 | -0.08 | 24 | ||
2021-05-10 | 2021-03-31 | -0.87 | -0.78 | 0.09 | 10 |
Axsome Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Axsome Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
11th of March 2025
Axsome Therapeutics, Inc. Receives 167.36 Average Price Target from Brokerages at thelincolnianonline.com
6th of March 2025
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals at finance.yahoo.com
5th of March 2025
Axsome Therapeutics Settles Sunosi Patent Litigation with Hikma Pharmaceuticals USA at finance.yahoo.com
4th of March 2025
AXSM Gets Positive FDA Feedback for Alzheimers Agitation Drug Filing at finance.yahoo.com
3rd of March 2025
Axsome Therapeutics Inc Prepares for sNDA Submission for AXS-05 in Alzheimers Disease ... at gurufocus.com
26th of February 2025
Axsome Therapeutics Inc Announces Participation in Upcoming Investor Conferences at gurufocus.com
25th of February 2025
Axsome Therapeutics SYMBRAVO Shows Promising Results in Migraine Treatment at gurufocus.com
24th of February 2025
Axsome Therapeutics Announces SYMBRAVO meloxicam and rizatript at gurufocus.com
18th of February 2025
Axsome Therapeutics Q4 2024 Earnings Call Transcript at fool.com
11th of February 2025
Axsome Therapeutics Stock Rises on Litigation Win at gurufocus.com
31st of January 2025
Axsome Therapeutics Hosts SYMBRAVO FDA Approval Virtual Investo at gurufocus.com
Axsome Therapeutics Investors Sentiment
The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.
Check out Axsome Therapeutics Backtesting and Axsome Therapeutics Hype Analysis. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.99) | Revenue Per Share | Quarterly Revenue Growth 0.66 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.